A Study of UK-369,003 on the Safety and Efficacy in Patients With COPD

A randomised, controlled study investigating the effect of UK-369,003 on exercise tolerance in patients with COPD

Completed

Looking for future studies?

Key information

Conditions

Pulmonary Disease, Chronic Obstructive Chronic Disease Disease Attributes Lung Diseases Lung Diseases, Obstructive Pathologic Processes Pathological Conditions, Signs and Symptoms Respiratory Tract Diseases

Age range

35 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Pfizer Investigational Site, Córdoba, Córdoba Province, Argentina

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

GOLD criteria 2 to 4
10 pack year history of smoking

Exclusion criteria

Women of child bearing potential

Treatment and study plan

UK-369,003

Drug

Primary outcomes

Effect on exercise tolerance

Secondary outcomes

Effect on lung function and quality of life

Sponsors and collaborators

Lead sponsor

Pfizer

Industry

Registry information

Official study title

A Multi-Centre, Multinational, Randomized, Double-Blind, Placebo Controlled, Proof Of Concept Trial To Assess The Effects Of A Subject-Optimized Dose Of UK-369,003 On Exercise Capacity In Subjects With Chronic Obstructive Pulmonary Disease

Important dates

Study start: 2004
Study completion: 2005
First posted: Sep 13, 2005
Registry last updated: Oct 13, 2006

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed